Genfit: Oddo BHF maintains 'buy' rating

(CercleFinance.com) - Oddo BHF reaffirmed its "outperform" rating on Genfit and raised its target price from 8.
8 to 9.3 euros, after good Phase III study results unveiled the previous day by Cymabay, Ipsen/Genfit's main competitor in primary biliary cholangitis.

"In terms of time-to-market, elafibranor is mechanically a few months ahead of schedule", continues the analyst, who does not alter his market assumptions, with a launch of this product in 2024 and peak sales of 411 million euros in 2030.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.